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The present study investigated the effects of resveratrol (RV), a polyphenol with potent antioxidant
properties, on oxidative stress parameters in liver and kidney, as well as on serum biochemical
parameters of streptozotocin (STZ)-induced diabetic rats. Animals were divided into six groups (n ¼ 8):
control/saline; control/RV 10 mg/kg; control/RV 20 mg/kg; diabetic/saline; diabetic/RV10 mg/kg; dia-
betic/RV 20 mg/kg. After 30 days of treatment with resveratrol the animals were sacriﬁced and the liver,
kidney and serum were used for experimental determinations. Results showed that TBARS levels were
signiﬁcantly increased in the diabetic/saline group and the administration of resveratrol prevented this
increase in the diabetic/RV10 and diabetic/RV20 groups (P < 0.05). The activities of catalase (CAT),
superoxide dismutase (SOD) and aminolevulinic acid dehydratase (d-ALA-D) and the levels of non
protein thiols (NPSH) and vitamin C presented a signiﬁcant decrease in the diabetic/saline group when
compared with the control/saline group (P < 0.05). The treatment with resveratrol was able to prevent
these decrease improving the antioxidant defense of the diabetic/RV10 and diabetic/RV20 groups
(P < 0.05). In addition, the elevation in serum alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST) and g-glutamiltransferase (g-GT) activities as well as in levels of urea, creatinine, cholesterol
and triglycerides observed in the diabetic/saline group were reverted to levels close to normal by the
administration of resveratrol in the diabetic/RV10 and diabetic/RV20 groups (P < 0.05). These ﬁndings
suggest that resveratrol could have a protector effect against hepatic and renal damage induced by
oxidative stress in the diabetic state, which was evidenced by the capacity of this polyphenol to modulate
the antioxidant defense and to decrease the lipid peroxidation in these tissues.
 2011 Elsevier Masson SAS. Open access under the Elsevier OA license.1. Introduction
Diabetes mellitus is a serious, complex chronic condition which
is a major source of ill health all over the world [1]. This metabolic
disorder is characterized by hyperglycemia and is associated witha/Centro de Ciências Naturais
-900 Santa Maria, RS, Brazil.
chmatz), veramorsch@gmail.
nder the Elsevier OA license.disturbances in carbohydrate, protein and fat metabolism which
occur secondary to an absolute or relative lack of insulin [1].
The precise cellular and molecular mechanism which underlies
the etiology and progression of diabetes is still not fully understood.
However, increasing evidence suggests that oxidative stress plays
a crucial role in the pathogenesis of diabetes and its complications
[2,3]. Elevated levels of blood glucose can induce non-enzymatic
and auto-oxidative glycosylation, increase polyol and hexosamine
pathway, promote protein kinase-C activation and lead to alter-
ations levels of inﬂammatory mediators, as well as in the status of
antioxidant defense [2e5]. These pathways are involved in the
R. Schmatz et al. / Biochimie 94 (2012) 374e383 375generation of reactive oxygen species (ROS) in diabetic state, which
directly contribute to the increase of oxidative stress in various
organs and tissues [2,5]. In addition to the pancreatic b-cells,
supraphysiological glucose levels are notorious to provoke oxida-
tive damage in hepatic and renal cells and consequently has been
associated with functional and morphological alterations in liver
and kidney of diabetic rats [6e8]. In fact, the liver is the focal organ
of oxidative and detoxifying processes as well as free radical reac-
tions and the biomarkers of oxidative stress are elevated in the liver
at an early stage in many diseases, including diabetes mellitus [8].
The most commonly recognized effect of oxidative stress is the
oxidation and damage of macromolecules such as proteins, lipids,
DNA, and enzymes involved in energy production, thereby
contributing to cellular injury, energetic deﬁcit, and the accelera-
tion of cell death through apoptosis and necrosis [9,10]. In both
human and animal diabetics, signiﬁcant increases in lip-
operoxidation products and/or decreases of some antioxidants have
been reported, and the presence of oxidative stress has been judged
by these indices [10,11].
The effect of ROS is balanced by the antioxidant action of non-
enzymatic antioxidants as well as by antioxidant enzymes. The
most efﬁcient enzymatic antioxidants involve superoxide dis-
mutase (SOD) and catalase (CAT) while non-enzymatic antioxi-
dants include non-proteics thiol, vitamin C and vitamin E [2,9,12].
These antioxidant defenses are extremely important since they
represent the direct removal of free radicals, providing maximal
protection for biological sites [12].
Of particular interest, aminolevulinate dehydratase (d-ALA-D),
also known as porphobilinogen synthase, is the second enzyme of
the heme pathway. This enzyme catalyzes the condensation of two
molecules of d-aminolevulinic acid (d-ALA), yielding to the
monopyrrole product porphobilinogen [13]. It is a metalloenzyme,
containing sulfhydryl (-SH) groups and zinc, which are essential for
its activity [14]. Notably, its cysteinyl residues are highly sensitive to
heavy metals [15], molecular oxygen, and other pro-oxidant
conditions such as hyperglycemia [16] that induces disulﬁde
bond formation and enzyme inhibition. Therefore, the sulfhydryl
enzyme d-ALA-D, used together with other parameters, can play an
important role as a marker of oxidative stress and impairment of
metabolic processes [15,16].
In addition, the use of compounds with antioxidant properties
has demonstrated a series of beneﬁcial effects in the prevention
and treatment of diabetic complications caused by oxidative stress
[17]. Resveratrol (3, 40, 5- trihydroxy-trans-stilbene), a natural
polyphenol foundmainly in grapes and redwine, has been reported
to have a wide range of biological properties [18]. The potent
antioxidant activity of resveratrol is well established in the litera-
ture [19], however, evidence has demonstrated that this compound
also possesses anti-inﬂammatory [20], antiaggregant and neuro-
protective properties [21,22]. Based on these ﬁndings, resveratrol
has become attractive as a therapeutic agent in the treatment of
a variety of pathologies including neurodegeneration, cancer,
cardiovascular disease and diabetes mellitus [20,22,23]. The
mechanisms underlying the beneﬁc effects of resveratrol are not
totally elucidated, but have been related mainly to its antioxidant
activity that has demonstrated to protect tissues, such as liver,
kidney and brain against a variety of damage caused by oxidative
stress [19,24].
Therefore, considering that resveratrol has important antioxi-
dant actions and that the oxidative stress has been associated with
the pathogenesis of different diabetic complications the aim of this
study was to investigate the effects of resveratrol in the oxidative
stress parameters in liver and kidney, and in the blood biochemical
parameters in streptozotocin (STZ)-induced diabetic rats, a well-
characterized animal model of type 1 diabetes, in order to verifythe potential therapeutic this compound in hepatic and renal
oxidative damage in diabetic state in rats with STZ-induced type 1
diabetes.
2. Materials and methods
2.1. Chemicals
Streptozotocin (STZ), resveratrol (3, 5, 40-trihydroxy-trans-stil-
bene, approximately 99% purity), d- aminolevulinic acid (d–ALA),
reduced glutathione (GSH), 5,50- dithio-bis-2-nitrobenzoic acid
(DTNB), tris (hydroxymethyl)-aminomethane GR, thiobarbituric
acid (TBA) and Coomassie brilliant blue G were purchased from
Sigma Chemical Co (St. Louis, MO, USA). All other reagents used in
the experiments were of analytical grade and of the highest purity.
2.2. Animals
Adult male Wistar rats (70e90 days; 180e280 g) from the
Central Animal House of the University Federal of Santa Maria
(UFSM) were used in this experiment. The animals were main-
tained at a constant temperature (23  1 C) on a 12 h light/dark
cycle with free access to food and water. All animal procedures
were approved by the Animal Ethics Committee from the Federal
University of Santa Maria (protocol under number: 21/2007).
2.3. Experimental induction of diabetes
Type 1 diabetes was induced by a single intraperitoneal injec-
tion of 55 mg/kg streptozotocin (STZ), diluted in 0.1 M sodium-
citrate buffer (pH 4.5). The age-matched control rats received an
equivalent amount of the sodium-citrate buffer. STZ-treated rats
received 5% of glucose instead of water for 24 h after diabetes
induction in order to reduce death due to hypoglycemic shock.
Blood samples were taken from the tail vein 48 h after STZ or
vehicle injection to measure glucose levels [25]. Glucose levels
were measured with a portable glucometer (ADVANTAGE, Boeh-
ringer Mannheim, MO, USA). Only animals with fasting glycemia
over 16 mmol/L were considered diabetic and used for the present
study. During the experiment the levels of blood glucose was
veriﬁed four times (2, 10, 20 and 30 days after the beginning of
treatment). The animals that maintained fasting glycemia higher
than 16 mmol/L were considered diabetic and selected for the
assays.
2.4. Treatment with resveratrol
The animals were randomly divided into six groups (8 rats per
group): Control/saline; Control/RV 10mg/kg; Control/RV 20 mg/kg;
Diabetic/saline; Diabetic/RV 10 mg/kg; and Diabetic/RV 20 mg/kg.
Two week after diabetes induction, the animals belonging to group
control/RV10 and diabetic/RV10 received 10 mg/kg of resveratrol
and the animals from control/RV20 and diabetic/RV20 groups
received 20 mg/kg of resveratrol, while the animals from control/
saline and diabetic/saline groups received saline solution. Resver-
atrol was freshly prepared in 25% ethanol and was administered
intraperitoneally at between 10 and 11 a.m. once a day during 30
days, at a volume not exceeding 0.1 ml/100 g rat weight.
The choice of the doses of 10 and 20 mg/kg of resveratrol was
made based in previous works of our research group, in which
diabetic rats were treated with resveratrol in the concentrations
of 10 and 20 mg/Kg (i.p.) [25e27,53,54] and also in several studies
that used theses same concentrations of resveratrol and obtained
beneﬁcial results [28e30]. Furthermore, the choice of these
concentrations take into account that red wine is the main
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concentration of trans-resveratrol in wine is 5 mg/L [32] and
moderate daily consumption of wine is 250 mL, the mean daily
intake of resveratrol under these conditions is 0.02 mg/kg. Thus,
we selected a dose that was 500 (10 mg/Kg) and 1000 (20 mg/kg)
times higher than this estimate to provide a sufﬁciently large
safety margin [28].2.5. Tissue preparation
Twenty-four hours after the treatment, the animals were
previously anesthetized with halothane and submitted to eutha-
nasia. The samples of liver and kidney were quickly removed,
placed on ice and homogenized within 10 min in cold 50 mM
TriseHCl pH 7.4 (1/10, w/v). The homogenate was centrifuged at
2000 g, at 4 C, for 10 min to yield the low speed supernatant (S1)
that was used immediately for TBARS, vitamin C, non-protein thiol
group (NPSH) and d ALA-D assay. Furthermore, during all proce-
dures the S1 was maintained on ice. It is important to note that the
immediate use of sample can prevent a possible alteration in the
sample caused by storage time and by freezing process. Moreover, it
is important point out that if any oxidation occurs spontaneously in
samples from diabetic and diabetic rats treated with resveratrol it
will be deleted, since all the procedures for the test samples and
control sample are carried out together. In order to perform SOD
and CAT assay, liver and kidney were diluted and homogenized as
described in the respective (Sections 2.7).2.6. Determination of lipid peroxidation
Lipid peroxidation in liver and kidney was estimated colori-
metrically by measuring thiobarbituric acid reactive substances
(TBARS) using the method described previously by Ohkawa et al.
[33]. In short, the reaction mixture contained 200 mL of samples of
S1 from liver and kidney or standard (MDA-malondialdehyde
0.03 mM), 200 mL of 8.1% sodium dodecylsulfate (SDS), 750 mL of
acetic acid solution (2.5 M HCl, pH 3.5) and 750 mL of 0.8% TBA. The
mixtures were heated at 95 C for 90 min. TBARS tissue levels were
expressed as nmol MDA/mg protein.2.7. Catalase (CAT) and superoxide dismutase (SOD) activities
For the CAT assay, liver and kidney were homogenized in 50mM
potassium phosphate buffer, pH 7.5, at a proportion of 1:9 (w/v) and
1:5 (w/v), respectively. The homogenate was centrifuged at 2000 g
for 10 min to yield a supernatant that was used for the enzyme
assay. CAT activity was measured by the method of Nelson and
Kiesow [34]. The reaction mixture contained 50 mM potassium
phosphate buffer (pH 7), 10 mMH2O2 and 20 mL of the supernatant.
The rate of H2O2 reaction was monitored at 240 nm for 2 min at
room temperature. The enzymatic activity was expressed in
units mg1 protein (One unit of the enzyme is considered as the
amount of CAT which decomposes 1 mmol of H2O2 per min at pH 7
at 25 C.)
With the purpose of performing the SOD assay [35] kidney and
liver was adequately dilutedwith TriseHCl pH 7.4 at a proportion of
1:40 (w/v) and 1:60(w/v) respectively. Brieﬂy, epinephrine
undergoes auto-oxidation at pH 10.2 to produce adrenochrome,
a colored product that was detected at 480 nm. The addition of
samples (10, 20, 30 mL) containing SOD inhibits the auto-oxidation
of epinephrine. The rate of inhibition was monitored during 180 s.
The amount of enzyme required to produce 50% inhibition was
deﬁned as 1 unit of enzyme activity.2.8. Vitamin C and non-protein thiol group (NPSH) content
Hepatic and renal vitamin C levels were determined by the
method of Jacques-Silva et al. [36]. Proteins of liver and kidneywere
precipitated in a cold 10% trichloroacetic acid (TCA) solution at
a proportion of 1:1 (v/v) and submitted to centrifugation again. This
supernatant was then used for analysis. A 300 mL aliquot of sample
in a ﬁnal volume of 575 mL of solutionwas incubated for 3 h at 37 C
then 500 mL H2SO4 65% (v/v) was added to the medium. The reac-
tion product was determined using a color reagent containing
4.5 mg/mL dinitrophenyl hydrazine (DNPH) and CuSO4 (0.075 mg/
mL). Vitamin C levels are expressed as mg ascorbic acid/g tissue.
NPSH was measured spectrophotometrically with Ellman’s
reagent [37]. An aliquot of 100 mL for liver and 200 mL for kidney in
a ﬁnal volume of 900 mL of solution was used for the reaction. The
reaction product was measured at 412 nm after the addition of
10 mM 5-5-dithio-bis (2-nitrobenzoic acid) (DTNB) (0.05 mL).
A standard curve using cysteine was added to calculate the content
of thiol groups in samples, and was expressed as mmol SH/g tissue.
2.9. d-Aminolevulinic acid dehydratase activity (d-ALA-D)
Hepatic and renal d-ALA-D activity was assayed according to the
method of Sassa [38] by measuring the rate of porphobilinogen
(PBG) formation, except that in all enzyme assays the ﬁnal
concentration of ALAwas 2.2 mM. An aliquot of 200 mL of sample S1
was incubated for 0.5 h (liver) and 1 h (kidney) at 37 C. The
reaction was stopped by addition of 250 mL of trichloroacetic acid
(TCA). The reaction product was determined using modiﬁed Ehr-
lich’s reagent at 555 nm. ALA-D activity was expressed as nmol
porphobilinogen (PBG) mg1 protein h1.
2.10. Biochemical analysis
The activities of the enzymes of serum aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT) and g-glutamyl-
transferase (g-GT) and the levels of urea and creatinine were
determined using standard methods on Cobas MIRA (Roche
Diagnostics, Basel, Switzerland) automated analyzer. In addition,
serum total cholesterol and triglycerides concentrations were
measured using standard enzymatic methods using Ortho-Clinical
Diagnostics reagents on the fully automated analyzer (Vitros 950
dry chemistry system; Johnson & Johnson, Rochester, NY, USA).
2.11. Protein determination
Protein was measured by the method of Bradford [39] using
bovine serum albumin as standard.
2.12. Statistical analysis
Statistical analysis was done by the commercial SPSS package
for Windows. All data were expressed as mean  S.D. Data were
analyzed statistically by one-way ANOVA followed by the Duncan’s
multiple tests. Differences were considered signiﬁcant when the
probability was P < 0.05.
3. Results
3.1. Blood glucose and body weight
The body weight and blood glucose levels determined at the
onset and at the end of the experiment are presented in Table 1. As
can be observed, the blood glucose levels and body weight at the
onset of the study showed no signiﬁcant differences among the
Table 1
The effect of different doses of resveratrol (RV) on body weight and fasting blood
glucose levels in control and diabetic rats at the onset and the end of the experiment
(30 days after resveratrol treatment).
Groups Blood glucose levels
(mmol/L)
Body weight (g)
Onset End Onset End
Control/saline 6.30  1.10 6.20  1.19 256  4.50 284  8.15
Control/RV 10 mg/kg 5.60  0.86 6.10  2.87 250  5.19 269  9.40
Control/RV 20 mg/kg 6.20  0.90 5.80  1.27 240  3.10 261  4.68
Diabetic/saline 6.10  1.28 25.10  1.26* 250  5.09 189  15.44*
Diabetic/RV10 mg/kg 5.80  2.13 25.60  2.24* 265  4.17 202  7.47*
Diabetic/RV20 mg/kg 5.90  1.19 23.20  1.52* 270  5.24 202  11.41*
Values are expressed as mean  S.D. *Signiﬁcant difference when compared to the
control/saline group (*P<0.05, n¼6e8). ANOVA-Duncan’s Test.
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signiﬁcantly increased, while the body weight was signiﬁcantly
decreased in diabetic/saline, diabetic/RV 10 and diabetic/RV20
groups (P < 0.05) when compared to the control/saline group.
However, the treatment with resveratrol had no effects on glucose
levels or on body weight in the diabetic/RV10 and diabetic/RV20
groups, when compared to the control/saline group. Similarly, no
signiﬁcant differences in glucose levels and body weight were
observed when resveratrol was administered per se in the control/
RV10 and control/RV20 groups at the end of the study when
compared to the control/saline group.Fig. 1. Levels of thiobarbituric acid reactive substances (TBARS) in liver (A) and kidney
(B) from STZ-induced diabetic rats and those treated with resveratrol. Bars represent
means  S.D. Groups with different letters are statistically different (P < 0.05; n ¼ 8).
ANOVA-Duncan’s Test.3.2. Lipid peroxidation
Hepatic and renal lipid peroxidation estimated by TBARS levels
is shown in Fig. 1A and B, respectively. As can be observed, TBARS
levels in liver and kidney were signiﬁcantly increased in the dia-
betic/saline group when compared to the control/saline group
(P < 0.05). However, treatment with resveratrol prevented an
increase of lipid peroxidation in both tissues in the diabetic/RV10
and diabetic/RV20 groups, when compared to the diabetic/saline
group (P < 0.05). No signiﬁcant difference on TBARS level in kidney
was observed in the control/RV10 and control/RV20 groups when
compared to the control/saline group.3.3. Catalase (CAT) and superoxide dismutase (SOD) activities
The effect of resveratrol on the activities of enzymatic antioxi-
dants CAT and SOD in hepatic and renal tissues are presented in
Figs. 2 and 3, respectively. Liver (Fig. 2A) and kidney (Fig. 2B) CAT
activity was signiﬁcantly decreased in the diabetic/saline group
when compared to the control/saline group (P < 0.05). The treat-
ment with resveratrol prevented this decrease in the enzyme
activity in liver and kidney in the diabetic/RV10 and diabetic/RV20
groups when compared to the diabetic/saline group (P < 0.05). InFig. 2. CAT activity in liver (A) and kidney (B) from STZ-induced diabetic rats and those
treated with resveratrol. Bars represent means  S.D. Groups with different letters are
statistically different (P < 0.05; n ¼ 8). ANOVA-Duncan’s Test.
Fig. 3. SOD activity in liver (A) and kidney (B) from STZ-induced diabetic rats and
those treated with resveratrol. Bars represent means  S.D. Groups with different
letters are statistically different (P < 0.05; n ¼ 8). ANOVA-Duncan’s Test.
Table 2
Non-protein thiols (NPSH) and ascorbic acid levels in liver and Kidney of STZ-
induced diabetic rats and treated with resveratrol (RV). Data are expressed as
means  S.D. Different letters in the same line indicate differences among the
groups. (P < 0.05; n ¼ 8 animals per group). ANOVA-Duncan’s test.
Groups NPSH (mmol SH/g tissue) AsA (mg ascorbic acid/g tissue)
Liver Kidney Liver Kidney
Control/saline 3.67  1.28a 3.35  0.33a 227.61  14.81a 161.12  11.21a
Control/RV10 3.80  0.86a 2.87  0.24a 235.31  11.38a 163.42  6.86a
Control/RV20 3.61  0.90a 2.86  0.27a 245.43  15.02a 156.72  9.51a
Diabetic/saline 2.26  0.69b 1.97  1.26b 181.36  12.08b 129.77  7.26b
Diabetic/RV10 3.82  0.56a 3.20  1.01a 199.11  7.52c 159.09  6.17a
Diabetic/RV20 3.46  0.35a 2.87  0.94a 233.46  10.01a 164.05  6.67a
Fig. 4. d-ALA-D activity in liver (A) and kidney (B) from STZ-induced diabetic rats and
those treated with resveratrol. Bars represent means  S.D. Groups with different
letters are statistically different (P < 0.05; n ¼ 8). ANOVA-Duncan’s Test.
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cantly the CAT activity in both types of tissues, in the control/RV10
and control/RV20 groups when compared to the control/saline
group.
Results found for SOD activity were similar to those obtained for
CAT activity. A signiﬁcant decrease in liver (Fig. 3A) and kidney
(Fig. 3B) SOD was observed activity in the diabetic/saline group
when compared to the control/saline group (P < 0.05). Treatment
with resveratrol prevented this decrease in SOD activity in both
tissues, in the diabetic/RV10 and diabetic/RV20 groups reaching
similar values to the control/saline group (P < 0.05). The adminis-
tration of resveratrol per se caused no signiﬁcant effect on SOD
activity in the control/RV10 or control/RV20 groups when
compared to the control/saline group.
3.4. Vitamin C and NPSH levels
Table 2 shows the hepatic and renal vitamin C and NPSH
content. As can be seen, in both liver and kidney vitamin C and
NPSH content was signiﬁcantly reduced in the diabetic/saline
group when compared to the control/saline group (P < 0.05).
However, the treatment with resveratrol was able to prevent the
reduction in the hepatic and renal content of these non enzymatic
antioxidants in the diabetic/RV10 and diabetic/RV20 group whencompared to diabetic/saline group (P< 0.05). When resveratrol was
given per se, no signiﬁcant difference in liver and kidney was
observed in the in the control/RV10 or control/RV20 groups when
compared to control/saline group.
3.5. d-ALA-D activity
Liver and kidney d-ALA-D (Fig. 4A and B, respectively) activity
presented a signiﬁcant decrease in the diabetic/saline group when
compared to the control/saline group (P < 0.05). The treatment
Table 3
Hepatic and renal markers of STZ-induced diabetic rats and treated with resveratrol (RV). Data are expressed as means  S.D. Different letters in the same column indicate
differences among the groups. (P < 0.05; n ¼ 8 animals per group). ANOVA-Duncan’s test.
Groups ALTa ASTa g-GTa Ureab Creatinineb
Control/saline 179.1  39.3a 64.0  13.5a 7.7  0.6a 52.1  3.8a 0.41  0.05a
Control/RV10 192.1  45.2a 55.1  6.5a 9.1  1.0a 44.1  1.9a 0.38  0.08a
Control/RV20 176.2  13.3a 57.8  8.9a 9.5  1.3a 54.2  4.5a 0.44  0.05a
Diabetic/saline 323.4  77.3b 94.4  19.6b 12.3  1.7b 86.4  9.5b 0.60  0.09b
Diabetic/RV10 192.1  24.8a 68.2  9.4ab 8.6  3.8a 62.2  7.2a 0.48  0.06a
Diabetic/RV20 197.8  64.5a 61.3  11.2a 8.4  0.92a 61.5  6.9a 0.35  0.08a
a Data of enzyme activities ALT, AST and g-GT are presented as U/l.
b Data of renal markers (urea and creatinine) are represented as mg/dl.
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types of tissues in the diabetic/RV10 and diabetic/RV20 groups
when compared to the diabetic/saline group (P < 0.05). Adminis-
tration of resveratrol per se did notmodify signiﬁcantly hepatic and
renal d-ALA-D activity in the control/RV10 or control/RV20 groups
when compared to the control/saline group.
3.6. Biochemical analysis
The activities of serum enzymes AST, ALT and g-GT were
signiﬁcantly higher in the diabetic/saline group when compared to
the control/saline group (P < 0.05) (Table 3). The treatment with
resveratrol prevented signiﬁcantly the rise of AST, ALT and g-GT
activities in the diabetic/RV10 and diabetic/RV20 groups (P < 0.05).
When resveratrol was given per se, no signiﬁcant differences were
observed in the control/RV10 or control/RV20 groups when
compared to the control/saline group.
Levels of renal function markers, urea and creatinine also pre-
sented a signiﬁcant increase in diabetic/saline group when
compared to control/saline group (P< 0.05) (Table 3). However, the
administration of resveratrol prevented this increase of urea and
creatinine levels in the diabetic/RV10 and diabetic/RV20 groups
(P< 0.05). The treatment with resveratrol per se caused no effect in
urea or creatinine levels in the control/RV10 or control/RV20
groups when compared to the control/saline group.
Cholesterol and triglycerides levels were signiﬁcantly increased
in the diabetic/saline group when compared to the control/saline
group (P < 0.05) (Table 4). Treatment with resveratrol prevented
the increase of cholesterol and triglyceride levels in the diabetic/
RV10 and diabetic/RV20 groups (P < 0.05). The administration of
resveratrol per se did not alter signiﬁcantly the cholesterol or
triglyceride levels in the control/RV10 and control/RV20 groups
when compared to the control/saline group.
4. Discussion
Extensive evidence has shown that chronic hyperglycemia leads
to a series of biochemical events resulting in the production of high
levels of ROS and eventual oxidative stress [2e5]. STZ-inducedTable 4
Cholesterol and triglycerides levels of STZ-induced diabetic rats and treated with
resveratrol (RV). Data are expressed as means  S.D. Different letters in the same
column indicate differences among the groups. (P < 0.05; n ¼ 8 animals per group).
ANOVA-Duncan’s test.
Groups Cholesterol
(mmol/L)
Triglycerides
(mmol/L)
Control/saline 1.56  0.12a 0.77  0.05a
Control/RV10 1.27  0.05a 0.68  0.06a
Control/RV20 1.64  0.17a 0.65  0.05a
Diabetic/saline 2.17  0.06b 1.00  0.04b
Diabetic/RV10 1.57  0.20a 0.77  0.07a
Diabetic/RV20 1.75  0.21ab 0.74  0.10adiabetes is a well-characterized experimental model for type 1
diabetes due to its ability to selectively destroy pancreatic islet
b-cells leading insulin deﬁciency and hyperglycemia [40]. Diabe-
togenic effect of STZ is mainly attributed to the excess production of
ROS leading to toxicity in pancreatic cells which reduces the
synthesis and the release of insulin, while affecting organs such as
liver, kidney, and hematopoietic system [40]. In view of this, several
experimental and clinical studies have indicated the potential
usefulness of polyphenolic compounds as antioxidants therapeutic
agents for the prevention and/or reduction of oxidative damage in
diabetes [41e43]. Thus, the effects of resveratrol on oxidative stress
in liver and kidney, as well as on blood biochemical parameters of
STZ-induced diabetic rats were investigated in this study.
Lipid peroxidation is considered a hallmark of oxidative stress,
in which ROS interact with polyunsaturated fatty acids, and leads
to the formation of lipid products such as MDA and 4-HNE
(4-hydroxynonenal), which then causing damages to the
membrane components of the cell, cell necrosis and inﬂammation
[44]. Extensive evidence has demonstrated that the increase of lipid
peroxidation plays an important role in the progression of diabetes
by altering the transbilayer ﬂuidity gradient, which could hamper
the activities of membrane-bound enzymes and receptors [3,45]. In
our study, there were signiﬁcant increases in lipid peroxidation in
liver and kidney of diabetic rats, as measured by TBARS formation
(Fig. 1A and B). These results are in agreement with several studies
that have reported an increase in TBARS levels in kidney, liver,
serum and erythrocytes of animal with experimental diabetes
[11,43,46,47]. Taken together these ﬁndings suggest that the
exposure to high glucose levels may elevate the generation of ROS
through the non-enzymatic glycation of protein and glucose auto-
oxidation. As a consequence, it provokes damage in structural and
functional integrity of hepatic and renal tissues, as evidenced by an
increase in the oxidative deterioration of the lipids of cellular
membrane in diabetic state.
In addition, the increased lipid peroxidation under diabetic
conditions could be due to increased oxidative stress in the cell as
a result of the depletion of antioxidant defense systems [48].
Antioxidant enzymes form the ﬁrst line of defense against ROS in
the organism include the enzymes SOD, CAT and GSH-Px, which
play an important role in scavenging the toxic intermediate of
incomplete oxidation. CATand SOD are the twomajor enzymes that
remove ROS in vivo. SOD catalyzes the dismutation of superoxide
anion (O2) into hydrogen peroxide (H2O2), which is then
degraded to H2O by CAT or by glutathione peroxidase. A decrease in
the activity of these antioxidants may lead to an excess of avail-
ability of O2 and H2O2, which in turn generates hydroxyl radicals,
resulting in initiation and propagation of lipid peroxidation
[2,9,48,49]. In line with this, in our study, it was observed
a decrease in the activities of antioxidants enzymes SOD and CAT in
liver and kidney of diabetic rats associated with a concomitant
increase in lipid peroxidation in these tissues (Figs. 2A, B and 3A, B).
Corroborating with these results, other studies have demonstrated
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are reduced in tissues of diabetic rats. This may result in a number
of deleterious effects due to the accumulation of ROS [4]. One
possible mechanism for this reduction in SOD and CAT activities
may be due to the inactivation caused by the excess of free radicals
and/or by non-enzymatic glycation due to the persistent hyper-
glycemia, which has been extensively reported to occur in diabetes
[2e5,50].
On the other hand, our study demonstrated that the treatment
with resveratrol (10 and 20mg/kg) prevented the increase in TBARS
levels and the reduction in SOD and CAT activity in liver and kidney
of STZ-induced diabetic rats, indicating a possible role of this
polyphenol in free radical inactivation and in the antioxidant
defense (Figs. 1A, Be3A, B). These results are consistent with
reductions in oxidative stress found in other studies, where the
resveratrol treatment greatly ameliorated antioxidants enzyme
activities and prevented the rise in lipid peroxides in tissue and
blood cells of diabetic animals [24,51e54]. In addition, Cao and Li
[55] and Leonard et al. [56] reported that resveratrol is able to up-
regulate mRNA expression for antioxidant enzymes and decrease
the activation of nuclear factor NF-kB (ROS-sensitive transcription
factor). Based on these ﬁndings, we can suggest that resveratrol is
able to modulate SOD and CAT activities, which may be very
important since it increases the scavenging capacity of ROS of liver
and kidney providing higher protection against oxidative damage
induced by diabetes in these tissues. In fact, the reactivation in SOD
activity promoted by resveratrol may accelerate the dismutation of
O2 to H2O2, which is quickly removed by CAT protecting the
hepatic and renal tissues of diabetic rats against highly reactive and
toxic hydroxyl radicals and consequently preventing the lipid per-
oxidation [20,56].
Numerous investigations have reported that resveratrol inhibits
effectively the lipid peroxidation of cellular membranes, the
protein oxidation as well as the DNA damage due its ability to
directly scavenge various free radicals, including superoxide radi-
cals and peroxyl and hydroxyl radicals [20,56,57]. Moreover, it
showed to reduce a-tocopheroxyl radical to regenerate the
endogenous tocopherol, which further strengthens the anti-
oxidant defense mechanism [58]. The capacity of resveratrol to
scavenge ROS may be attributed to a hydrogen-electron donation
from its hydroxyl groups [59]. It has been reported that due to
hydroxylated structure of resveratrol, it can form a radical deriva-
tive stabilized by the delocalization of two electrons between the
two aromatic cycles and the methylene bridge joining these two
cycles [60]. It is important to observe that due to its highly lipo-
philic character resveratrol is able to bind the lipoprotein particles
suggesting that this event improved its antioxidant activity [61].
Simultaneously with the decrease in the activity of the antiox-
idants enzymes, ruined antioxidant competence of non-enzymatic
antioxidants such as non-protein thiols and vitamin C have been
reported in diabetes [62e64]. In our study, a marked decrease in
NPSH and vitamin C content was observed in liver and kidney of
diabetic rats, as reported by other studies [52,63,64] (Table 2). The
decrease in hepatic and renal NPSH levels in diabetic rats may
represent a depletion of this antioxidant due to its increased
utilization in removing H2O2 and other peroxides produced in
excess due to oxidative stress [65]. On the other hand, the reduction
in vitamin C content in the diabetes may be attributed to elevated
utilization of this antioxidant in trapping the oxyradicals and/or to
a decrease in the GSH level, since GSH is required for the recycling
of ascorbic acid [66]. This deﬁciency in NPSH levels, mainly GSH,
and in the vitamin C content found in our study can increase the
susceptibility to oxidative damage in hepatic and renal cells and
may contribute to the pathogenesis of complications associated
with the chronic diabetic state [67].In our study, the treatment with resveratrol restored NPSH and
vitamin C content in liver and kidney of diabetic rats close prox-
imity to normal levels, which in turn reveals the antioxidant
potential of resveratrol (Table 2). Similarly, Palsamy et al. [43,51]
also observed that resveratrol was able to prevent the decrease in
GSH levels in liver and pancreas of diabetic rats. In fact, polyphenols
are reported to enhance the activity of g-glutamylcysteine
synthetase and demonstrated simultaneous escalation in the
intracellular GSH level [41]. In addition, data of literature demon-
strated that elevated levels of GSH protects cellular proteins against
oxidation through glutathione redox cycle and also directly
detoxiﬁes ROS [67]. In this line, we can suggest that a prevention of
a decrease in NPSH content in liver and kidney of diabetic rats
found in our study could be in part responsible for the decrease in
ROS formation and in the lipid peroxidation levels and the resultant
of low oxidative stress obtained in vivo in the animals treated with
resveratrol.
Persuasive evidence has indicated that d-ALA-D enzyme is
highly sensitive to the presence of a variety of pro-oxidant
elements, which oxidize -SH groups of this enzyme impairing its
activity [15,68]. The inhibition of d-ALA-D activity may prejudice
heme biosynthesis and can result in the accumulation of amino-
levulinic acid which, under physiologically conditions, can have
pro-oxidant effects contributing to the oxidative stress [69]. In line
with this, in the present study, the activity of d-ALA-D was signif-
icantly decreased in hepatic and renal tissues of diabetic rats
(Fig. 4A and B). Our results are in accordance with data found in
human and experimental diabetes, where a signiﬁcant inhibition of
d-ALA-D is described and has been related mainly to high glucose
levels and overproduction of ROS [16,64,70]. Thus, we can suggest
that the inhibition of d-ALA-D activity in liver and kidney of diabetic
rats may be a consequence of either the glycation in the lysine
residue from the active site of d-ALA-D, which is involved in the
formation of the Schiff basis with the ﬁrst molecule of ALA [71], or
by oxidation of essential reduce cysteinyl residues of the enzyme by
ROS [64,68,72]. Furthermore, the decrease in d-ALA-D activity
found in our study may be linked to the signiﬁcant reduction in the
antioxidant defenses in hepatic and renal tissues of diabetic rats,
especially in NPSH content, which is responsible for preventing the
oxidation of the sulphydryl groups necessary for the activity of this
enzyme [15].
The treatment with resveratrol at doses of 10 and 20 mg/kg was
able to prevent the inhibition in d-ALA-D activity in liver and kidney
of diabetic rats suggesting that this compound can prevent the
oxidation of essential -SH groups located at its active site of d-ALA-D
and consequently its inhibition (Fig. 4A and B). Indeed, in our study
resveratrol prevented the reduction of NPSH levels in hepatic and
renal tissues in STZ- induced diabetic rats; hence, it could be
expected to protect other endogenous thiols such as those found in
d-ALA-D enzyme. Consequently, we can suggest that the prevention
of a decrease in NPSH content as well as a decrease of oxidative
stress in diabetic rats by resveratrol could be associated with
a prevention of a decrease of d-ALA-D activity. Furthermore, this
study clariﬁes that the inhibition of d -ALA-D enzyme is not closely
related to the development of hyperglycemia in rats, pointing out
the importance of antioxidants as resveratrol to minimize delete-
rious effects of diabetes in activity of this biologically important
enzyme.
Another important aspect to be discussed in this study is serum
aminotransferases activities, which have long been considered as
sensitive indicators of hepatic damage [73]. Injury to the hepato-
cytes alters their transport function and membrane permeability,
leading to leakage of enzymes from the cells [73,74]. Therefore, the
marked release of ASTandALT from liver cytosol into circulation and
an increase of g-GT, amembrane enzyme, indicate severe damage to
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activities of AST, ALT, and g-GT found in this study may be inter-
preted as a result of the liver cell destruction or changes in the
membrane permeability indicating severe hepatocellular damage is
induced by diabetes, which is in accordance with other reports
[64,74,75] (Table 3). The administration of resveratrol in doses of 10
and 20mg/Kgwas able to protect against the increase in the activity
of these enzymes in diabetic rats, demonstrating the protective
effect of this polyphenol against hepatic damage induced by dia-
betic state (Table 3). These results are in agreement with those
found in studies using resveratrol [51,76] and other antioxidants as
rutin [76], caffeic acid and quercetin [77] and can be attributed to
the capability of resveratrol to conserve the membrane integrity of
cellular organelles in the diabetic state. Indeed, in our study
resveratrol was able to prevent the lipid peroxidation in hepatic
tissue.
In addition to the hepatic damage, in the current study, diabetic
rats also presented renal damages that were evidenced by the
elevation in serum urea and creatinine levels, which are considered
as signiﬁcant markers of renal dysfunction [78] (Table 3). Of great
importance, resveratrol prevented the increase in the levels of urea
and creatinine in diabetic rats. These ﬁndings suggest that resver-
atrol possesses the potential to attenuate renal injury caused by
hyperglycemic state and this can be associated directly with the
antioxidant capacity of this polyphenol, which protects the kidneys
against oxidative damage, as evidenced in this and other studies
[79,80].
Another important aspect to be discussed is that, in contrast
with our results, Hassan-Khabbar et al. [80] related that the dose of
20 mg/kg of trans-resveratrol became pro-oxidant with an aggra-
vation of liver injury associated with a depletion of total and
reduced glutathione levels and a decrease of antioxidant enzyme
activities. In addition, Gadacha et al. [81] related a possible pro-
oxidant effect of resveratrol at 0.8, 2, and 5 mg/kg, depending on
day/night rhythm. In fact, studies has related that depending of the
concentration of the phytoalexin and on the cell type, the resver-
atrol can exhibit pro-oxidant properties, leading to oxidative
breakage of cellular DNA in the presence of transition metal ions
such as copper. Recently, it has been proposed that such a pro-
oxidant action could be a common mechanism for anticancer and
chemopreventive properties of plant polyphenols [82]. Further-
more, it has been suggested that resveratrol can work as a pro-
oxidant under low oxidative conditions, while it becomes antioxi-
dant under strong oxidative conditions [81]. Therefore, studies
have shown that resveratrol possess biphasic function [83].
However, its pro-oxidant or antioxidant action appears to be
depending on the dose, environmental factors, interactions with
other compounds, medications, cell types and different patholog-
ical conditions [81,84]. For example, in our study the dose of 20mg/
kg had an important antioxidant effect in diabetic rats, while in
other studies, in different pathologic conditions, the same dose
showed pro-antioxidant effects [80]. Thus, more research is needed
to understand the action of resveratrol on all cell types and
conditions, and the optimum therapeutic concentration that
applies to each condition in order to gain a complete understanding
of the biphasic response of resveratrol.
Literature data have showed that the diabetes is usually asso-
ciated with abnormal high levels of serum lipids, which may
contribute to the development and progression of micro- and
macrovascular complications [85]. In our study, there is a signiﬁ-
cant rise in serum cholesterol and triglycerides levels in diabetic
rats (Table 4). However, when diabetic rats received resveratrol the
levels of serum triglycerides and cholesterol presented a signiﬁcant
decrease. These results are supported by other works that have
reported that administration of resveratrol improved lipid proﬁleincluding reduction of serum cholesterol levels [86]. In addition,
resveratrol appears to be beneﬁcially modulating the lipid and
lipoprotein levels, inhibiting hepatic triglycerides synthesis and
reducing cholesterol and triglycerides accumulation in liver [87].
Considering the cholesterol lowering property of resveratrol, it has
been suggested that it may act as inhibitor for some enzymes such
as hydroxy methyl glutaryl CoA reductase, which participates in
the cholesterol synthesis [86,87]. Based on these results, we can
suggest that resveratrol improves the dyslipidemiawhile inhibiting
the progression of hepatic and renal dysfunction in STZ-induced
diabetic rats.
An important datum of this study is that despite the absence of
the effect of resveratrol in the reduction of hyperglycemia of the
diabetic rats treated with this polyphenol, there was a reduction of
death of these animals when compared with the animals of dia-
betic/saline group. Indeed, only about 50% of the animals of dia-
betic/saline group survived until the end of experiment, while in
the groups of diabetic rats treated with resveratrol there was
a survival of about of 80% of the animals (data not shown). Litera-
ture data have demonstrated that resveratrol extends the lifespan
of mice through the overexpression of sirtuin 1 in a yeast diet and is
linked to longer life in humans [88,89]. In addition, Baur et al. [90]
shows that resveratrol shifts the physiology of middle-aged mice
on a high-calorie diet towards that of mice on a standard diet and
signiﬁcantly increases their survival. Although our study indicates
an increase in survival of diabetic rats treated with resveratrol,
our protocol lasted 30 days, therefore, no full response can be
obtained and a longer-lasting protocol could determine the effects
of resveratrol on lifespan of STZ-induced diabetic rats. Neverthe-
less, the treatment with resveratrol produced changes associated
with longer lifespan, including an increase in antioxidant defense
system and consequently a decrease of the oxidative stress in liver
and kidney of diabetic rats.
In conclusion, the ﬁndings of the present study demonstrated
that resveratrol treatment may provide effective protection against
oxidative damage in liver and kidney STZ- induced type 1 diabetic
rats, since this compound was able to ameliorate enzymatic and
non-enzymatic antioxidant defense system and to prevent the lipid
peroxidation in these tissues. Moreover, it is important to point out
that this is the ﬁrst study to investigate the effects of resveratrol on
d-ALA-D activity in diabetic rats demonstrating the important role
of this enzyme as amarker of oxidative stress. Taken together, these
results may contribute to a better understanding of the hep-
atoprotective and renoprotective role of resveratrol, emphasizing
the inﬂuence of this polyphenol and other antioxidants in the diet
for human health, possibly preventing hepatic and renal compli-
cations associated with diabetes mellitus.
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